The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis
The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget.
Source: Research in Social and Administrative Pharmacy - Category: Pharmaceuticals Authors: Mohammed I. Aladul, Raymond W. Fitzpatrick, Stephen R. Chapman Source Type: research
More News: Budgets | Enbrel | European Medicines Agency (EMA) | Gastroenterology | Humira | Pharmaceuticals | Remicade | Rheumatology